Montalbano, S., Krebs, M. D., Rosengren, A., Vaez, M., Hellberg, K. L. G.
, Mortensen, P. B., Børglum, A. D., Geschwind, D. H., Raznahan, A., Thompson, W. K., Helenius, D., Werge, T., Ingason, A. & iPSYCH Investigators (2024).
Analysis of exonic deletions in a large population study provides novel insights into NRXN1 pathology.
npj Genomic Medicine,
9(1), Article 67.
https://doi.org/10.1038/s41525-024-00450-8
Hvingelby, V., Carra, R. B.
, Terkelsen, M. H., Hamani, C., Capato, T., Košutzká, Z., Krauss, J. K., Moro, E.
, Pavese, N., Cury, R. G. & Gait Study Group (2024).
A Pragmatic Review on Spinal Cord Stimulation Therapy for Parkinson's Disease Gait Related Disorders: Gaps and Controversies.
Movement Disorders Clinical Practice,
11(8), 927-947.
https://doi.org/10.1002/mdc3.14143
Santos, J., Cuellar, J., Pallarès, I., Byrd, E. J., Lends, A., Moro, F., Abdul-Shukkoor, M. B., Pujols, J., Velasco-Carneros, L., Sobott, F.
, Otzen, D. E., Calabrese, A. N., Muga, A.
, Pedersen, J. S., Loquet, A., Valpuesta, J. M., Radford, S. E. & Ventura, S. (2024).
A Targetable N-Terminal Motif Orchestrates α-Synuclein Oligomer-to-Fibril Conversion.
Journal of the American Chemical Society,
146(18), 12702-12711.
https://doi.org/10.1021/jacs.4c02262
Vieira de Sá, R., Sudria-Lopez, E., Cañizares Luna, M., Harschnitz, O., van den Heuvel, D. M. A., Kling, S., Vonk, D., Westeneng, H. J., Karst, H., Bloemenkamp, L., Varderidou-Minasian, S., Schlegel, D. K., Mars, M., Broekhoven, M. H., van Kronenburg, N. C. H., Adolfs, Y., Vangoor, V. R., de Jongh, R., Ljubikj, T. ... Pasterkamp, R. J. (2024).
ATAXIN-2 intermediate-length polyglutamine expansions elicit ALS-associated metabolic and immune phenotypes.
Nature Communications,
15(1), Article 7484.
https://doi.org/10.1038/s41467-024-51676-0
Pirhaghi, M., Mamashli, F., Moosavi-Movahedi, F., Arghavani, P., Amiri, A., Davaeil, B., Mohammad-Zaheri, M., Mousavi-Jarrahi, Z., Sharma, D., Langel, Ü.
, Otzen, D. E. & Saboury, A. A. (2024).
Cell-Penetrating Peptides: Promising Therapeutics and Drug-Delivery Systems for Neurodegenerative Diseases.
Molecular Pharmaceutics,
21(5), 2097-2117.
https://doi.org/10.1021/acs.molpharmaceut.3c01167